期刊文献+

液态芯片检测多种肿瘤标志物在胃癌中的应用 被引量:5

Clinical Significance of Detecting Multiple Tumor-Markers with Liquid Chip Technology in Gastric Cancer
原文传递
导出
摘要 目的①通过液态芯片(liquid Chip)技术检测胃癌(gastric cancer)患者和正常人群血清中多种肿瘤标志物(tum or markers)表达的差异;②探讨运用液态芯片技术进行血清肿瘤标志物联合检测对胃癌的诊断价值。方法应用多肿瘤标志物液态芯片检测系统,检测82例胃癌患者和82例正常对照者血清中4种常见肿瘤标志物。结果①胃癌组CEA、CA125、CA242、CYFRA211表达水平均显著高于正常对照组,差异有统计学差异意义(P<0.05);②胃癌组CEA、CA125、CA242、CYFRA211联合检测的阳性率是73.2%,而胃癌组单项检测CEA、CA125、CA242、CYFRA211的阳性率分别为41.5%、31.7%、37.8%、29.3%,均显著低于联合检测的阳性率(P<0.01)。结论血清CEA、CA125、CA242、CYFRA211是胃癌辅助诊断的理想指标;应用液态芯片技术联合检测肿瘤标志物CEA、CA125、CA242和CYFRA211有利于提高检出阳性率。 Objective To explore the diagnosis value of combined detection of serum multi-tumor markers(TM) by liquid chip detective system in patients with gastric cancer. Methods Four kinds of tumor markers(CEA,CA125,CA242 and CYFRA211) in the serum of 82 patients with gastric cancer and 82 normal subjects were detected by the multi-tumor markers liquid chip diagnostic system. Results (1)The serum levels of CEA,CA125 ,CA242 and CYFRA211 in the patients with gastric cancer were significantly higher than that in control groups(P 〈 0.05 ) ;(2)The sensitivity of combined detection of CEA, CA125, CA242 and CYFRA211 in the patients with gastric cancer was 73.2% ,and was obviously higher than the positive rate(41.5% for CEA,31.7% for CA125, 37.8% for CA242 and 29.3% for CYFRA211, respectively) of single tumor marker detection (P 〈 0. 01 ). Conclusion CEA, CA125,CA242 and CYFRA211 could be regarded as valuable tumor marker for gastric cancer. The combined detection of CEA, CA125, CA242 and CYFRA211 by the liquid chip technology can enhance the diagnostic sensitivity of gastric cancer by increase the positive rate.
出处 《中华全科医学》 2010年第12期1534-1534,1547,共2页 Chinese Journal of General Practice
关键词 液态芯片 胃肿瘤 肿瘤标志物 Liquid chip Gastric Cancer Tumor Markers
  • 相关文献

参考文献10

  • 1Jacobs I J, Menon U. Progress and challenges in screening for early detection of ovarian cancer [ J ]. Mol Cell Proteomics, 2004,3 (4) : 355- 366. 被引量:1
  • 2Sturgeon CM,Duffy MJ,Stenman UH,et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers [J]. Clin Chem,2008,54(12) :11-79. 被引量:1
  • 3Chapman K. The Protein Chip Biomarker System from Ciphergen Biosysterns : a novel proteomics platform for rapid biomarker discovery and validation[J]. Biochem Soc Trans,2002,30(2) :82-87. 被引量:1
  • 4Sreekumar A, Chinnaiyan AM. Using protein microarrays to study cancer [ J ]. Biotechniques ,2002, Supp1:46-53. 被引量:1
  • 5Balachandra K,Laisupasin P,Dhepakson P,et al. Preliminary clinical evaluation of a protein chip for tumor marker serodiagnosis of various cancers[ J ]. Asian Pac J Allergy Immunol,2003,21 (3) :171-178. 被引量:1
  • 6Dacic S. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis[ J]. Expert Rev Mol Diagn ,2007,7( 1 ) :77-86. 被引量:1
  • 7Kilic A,Schuchert M J, Luketich JD,et al. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum [ J ]. J Thorac Cardiovasc Surg,2008,136 ( 1 ) : 199-204. 被引量:1
  • 8Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer[ J]. Cancer Sci ,2009,100 (2) :195-199. 被引量:1
  • 9Chen C,Chen LQ,Chen LD,et al. Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement : analysis of 100 cases [ J ]. Hepatogastroenterology, 2008,55 (84) :991-997. 被引量:1
  • 10Dacic S. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis [ J]. Expert Rev Mol Diagn ,2007,7( 1 ) :77-86. 被引量:1

同被引文献52

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部